This multi-organ synergistic regulatory mode allows GLP-1RA to improve the insulin resistance state of T2DM from the source, rather than simply relying on “exogenous supplementation” or “forced secretion” of insulin for symptomatic treatment. Here, INS is linked to type 2 diabetes mellitus.